{"id":"transcon-pth","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Injection site reaction"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"TransCon PTH is a prodrug that is designed to provide a sustained release of parathyroid hormone, mimicking the natural physiological profile of endogenous parathyroid hormone. This allows for a more consistent and predictable effect on bone metabolism, potentially reducing the risk of osteoporosis and fractures.","oneSentence":"TransCon PTH is a long-acting parathyroid hormone analogue designed to mimic the natural physiological profile of endogenous parathyroid hormone.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:39:47.229Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of osteoporosis in men and women"}]},"trialDetails":[{"nctId":"NCT07081997","phase":"PHASE3","title":"A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism","status":"NOT_YET_RECRUITING","sponsor":"Ascendis Pharma Bone Diseases A/S","startDate":"2026-04","conditions":"Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases","enrollment":36},{"nctId":"NCT04701203","phase":"PHASE3","title":"A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Daily in Adults With Hypoparathyroidism","status":"COMPLETED","sponsor":"Ascendis Pharma Bone Diseases A/S","startDate":"2021-02-16","conditions":"Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases","enrollment":84},{"nctId":"NCT07299838","phase":"","title":"Palopegteriparatide in Chronic Hypoparathyroidism","status":"COMPLETED","sponsor":"National and Kapodistrian University of Athens","startDate":"2024-06-01","conditions":"Hypoparathyroidism","enrollment":90},{"nctId":"NCT05387070","phase":"PHASE3","title":"PaTHway CHINA TRIAL: A Trial to Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism","status":"COMPLETED","sponsor":"Visen Pharmaceuticals (Shanghai) Co., Ltd.","startDate":"2021-07-28","conditions":"Hypoparathyroidism, Parathyroid Hormone Deficiency, Endocrine System Diseases","enrollment":81},{"nctId":"NCT05654701","phase":"","title":"Expanded Access Program of Palopegteriparatide in Patients With Hypoparathyroidism","status":"APPROVED_FOR_MARKETING","sponsor":"Ascendis Pharma Bone Diseases A/S","startDate":"","conditions":"Hypoparathyroidism","enrollment":""},{"nctId":"NCT04009291","phase":"PHASE2","title":"A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism","status":"COMPLETED","sponsor":"Ascendis Pharma A/S","startDate":"2019-08-27","conditions":"Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases","enrollment":59}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":17,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"TransCon PTH","genericName":"TransCon PTH","companyName":"Visen Pharmaceuticals (Shanghai) Co., Ltd.","companyId":"visen-pharmaceuticals-shanghai-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TransCon PTH is a long-acting parathyroid hormone analogue designed to mimic the natural physiological profile of endogenous parathyroid hormone. Used for Treatment of osteoporosis in men and women.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}